Pharma’s Digital Directive: Not If, But How
The transformative potential of the digital revolution is apparent. However, pharma companies need to think pragmatically about how digital applies to what they already do.
Bionest Partners is a global consulting firm focused on Pharma, Biotech, Medical Device and Diagnostics.
Curing What Ails Alzheimer’s Drug Development
Biomarkers will be key to winning the race to a successful Alzheimer’s drug, as we present in our latest In Vivo article.
One-Shot Curative Treatments: A Pharma and Payer Revolution
Orphans Should Live Alone
Read our recent article for In Vivo with advice for pharma interested in rare diseases.
How Immuno-Oncology Is Turning Biomarker Development On Its Head
This In Vivo article covers the challenges in orchestrating a biomarker program in immuno-oncology.
New Big Data Initiatives in Oncology
Read our take on the emerging field of ‘Real-time Oncology’ – the ability to constantly monitor changes in a patient’s disease and adjust treatment accordingly.
About Bionest
We help clients navigate complex product development and commercialization issues in order to drive growth, create value and gain competitive advantage. We also offer our expertise and analytic skills to support investors with due diligence assignments. Our deep content experience, combined with our collaborative and hands-on approach results in practical solutions that drive internal alignment at the corporate, portfolio, and brand levels.
News & Views
Check out our blog for news and commentary on the latest issues in pharma.
